MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MDSpire News

  • July 28, 2026
May Lower RFR Signal Repeat Revascularization?
  • Andrea Surnit
  • July 28, 2026
  • 4 min

Objective: To evaluate the association between nonischemic resting full-cycle ratio (RFR) values and cardiovascular outcomes, particularly focusing on repeat re

...more

Kff Health News

  • July 28, 2026
Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead
  • Kate Wells
  • Stephanie Armour
  • July 28, 2026
  • 6 min
  1. Food safety leaders express concern that federal funding cuts hinder the detection and management of foodborne illnesses like cyclospora.
  2. The Trump administration's cuts to public health funding have affected the FoodNet program, which tracks several dangerous pathogens.
  3. States no longer have to report cases of listeria and campylobacter, which complicates outbreak identification and response.
  4. Food safety inspections by the FDA have significantly decreased, with the agency failing to meet mandated inspection targets since 2018.
  5. Michigan has reported over 7,000 cases of cyclosporiasis, highlighting the impact of an underfunded public health system.
...more

The Medicine Maker

  • July 28, 2026
The New Rules of Global Drug Development
  • James Strachan
  • July 28, 2026
  • 9 min

Objective: To explore the evolving landscape of drug development in the post-COVID era, focusing on funding models, investor expectations, and innovative approa

...more

The Pathologist

  • July 28, 2026
Breathe Here to Test for IBS
  • Helen Bristow
  • July 28, 2026
  • 4 min
  1. IBS affects an estimated 17% of adults in the UK, with SIBO recognized as a contributing factor.
  2. OMED Health developed a home-testing kit for SIBO, linked to an expert diagnostic service.
  3. Welbeck Health Partners launched a home-based testing pathway after a successful three-month evaluation.
  4. The home testing kit allows patients to complete tests conveniently at home, improving compliance and satisfaction.
  5. Patients receive instant results via an app, enhancing turnaround time compared to traditional clinic-based testing.
...more

The Analytical Scientist

  • July 28, 2026
Breaking Water's Bonds
  • July 28, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Ophthalmologist

  • July 28, 2026
Pinhole Optics Meet Cataract Surgery
  • July 28, 2026
  • 3 min

Objective: To evaluate the outcomes of the IC-8 pinhole intraocular lens (IOL) in patients with cataract and significant corneal comorbidities. Approach: Study

...more

The Ophthalmologist

  • July 28, 2026
The Hormone Link in Keratoconus
  • July 28, 2026
  • 2 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Pathologist

  • July 28, 2026
AMP Honors Leaders in Molecular Diagnostics
  • July 28, 2026
  • 3 min
  1. The Association for Molecular Pathology will present its 2026 honors at the Annual Meeting & Expo in Seattle this November.
  2. Elaine S. Jaffe will receive the Award for Excellence in Molecular Diagnostics for her contributions to lymphoma diagnosis and classification.
  3. Laura J. Tafe is awarded the Jeffrey A. Kant Leadership Award for her leadership and service to AMP, including her presidency in 2023.
  4. Daniel E. Sabath has been named the recipient of the Meritorious Service Award for over 25 years of service to AMP and mentorship.
  5. AMP President Aaron D. Bossler stated that the awards honor recipients' leadership and commitment to advancing molecular diagnostics.
...more

MDSpire News

  • July 27, 2026
Colorectal Cancer Screening Blood Test Approved by FDA
  • Kathryn Wighton
  • July 27, 2026
  • 2 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

MDSpire News

  • July 27, 2026
FDA Approves Centanafadine for ADHD
  • Kathryn Wighton
  • July 27, 2026
  • 3 min
  1. The FDA has approved centanafadine (SIMTRIYO) for treating ADHD in patients aged 6 years and older.
  2. Centanafadine's approval is based on four phase 3 randomized, double-blind, placebo-controlled trials.
  3. Statistically significant improvements in ADHD symptoms were observed in both adult and pediatric studies.
  4. Common adverse reactions included rash, decreased appetite, and headache, varying by age group.
  5. ADHD affects approximately 7 million pediatric patients and 15.5 million adults in the US.
...more

The Medicine Maker

  • July 27, 2026
This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer
  • July 27, 2026
  • 5 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

MDSpire News

  • July 27, 2026
Mesh Hysteropexy May Improve Long-Term Prolapse Outcomes
  • Andrea Surnit
  • July 27, 2026
  • 4 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

MDSpire News

  • July 27, 2026
Does Exercise Inhibit Myopia Progression in Children?
  • Andrea Surnit
  • July 27, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Medicine Maker

  • July 27, 2026
The Confidentiality Barrier to AI-Enabled Drug Development
  • Timothy Pas
  • Laure Descamps
  • July 27, 2026
  • 4 min
  1. AI is transforming drug development by improving predictions of solubility and bioavailability, addressing challenges from molecular complexity.
  2. Confidentiality requirements hinder the use of client-owned molecular data in AI platforms, limiting CDMO capabilities.
  3. Developing in-house AI systems poses challenges related to data ownership and the need for client authorization for model training.
  4. AI outputs should be seen as hypothesis-generating, requiring laboratory validation due to the complexity of solubility and bioavailability.
  5. AI is expected to enhance drug development efficiency, but empirical testing will remain essential to confirm predictions.
...more

The Ophthalmologist

  • July 27, 2026
Balance Ophthalmics Appoints New CCO
  • July 27, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Ophthalmologist

  • July 27, 2026
Who Owns the Outcome?
  • Mfazo Hove
  • July 27, 2026
  • 12 min
  1. Patients paying for private eye surgery expect comprehensive care, including management of complications, but this expectation may not be met.
  2. In the UK, private ophthalmology often involves three separate entities: the surgeon, the hospital, and the provider, each with distinct responsibilities.
  3. A dropped nucleus during surgery illustrates the accountability gap, as patients may find themselves navigating different systems for complication management.
  4. Consent forms signed by patients do not typically clarify post-complication management responsibilities or coverage, leading to confusion.
  5. The fragmentation of care in private ophthalmology raises significant questions about ownership of outcomes and continuity of care.
...more

The Analytical Scientist

  • July 27, 2026
Scaling Genomics for Precision Medicine
  • July 27, 2026
  • 5 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Pathologist

  • July 27, 2026
England Expands Newborn SMA Screening
  • July 27, 2026
  • 3 min
  1. England will expand newborn genetic screening for spinal muscular atrophy (SMA) through the national heel-prick screening program.
  2. The initiative aims to identify affected infants before symptoms develop, enhancing treatment effectiveness.
  3. Laboratory testing for SMA screening is expected to begin in October 2026, three months earlier than initially planned.
  4. The program will generate real-world evidence through a £4.1 million evaluation funded by the National Institute for Health and Care Research.
  5. Implementation will continue through 2027, ensuring all newborn screening laboratories in England offer the SMA test.
...more